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ABSTRACT 
 
Background: Acinetobacter species have emerged as opportunistic pathogens and can cause a wide range of 
healthcare associated infections like ventilator associated pneumonia, meningitis, and bacteremia, urinary tract 
infections, peritonitis, etc. Acinetobacter spp, most often multi-drug resistant , are difficult to treat pathogens and 
can lead to treatment failure. Methods: Our study was conducted to determine the frequency and antimicrobial 
resistance pattern of Acinetobacter species from various clinical samples. The isolates were identified by standard 
protocols and further tested for antimicrobial resistance by Kirby-Bauer disk diffusion method as per CLSI 
guidelines. Results: From 261 Acinetobacter isolates, maximum (39.5%) were obtained from pus/swab, followed by 
blood (31%), urine (19.9%) and other samples (9.6%). Acinetobacter species were resistant to ciprofloxacin 
(73.4%), amikacin (57.9%), gentamicin (70.4%), ceftazidime (82.9%), cefoperazone (82.4%), ampicillin/sulbactum 
(58%). The low resistant pattern of  sulbactam-ceftazidime (18.4%), piperacillin/tazobactam (15.1%), imipenem 
(23.6%), indicate that they are effective drugs. All  the isolates were found to be sensitive to colistin. Conclusion: 
Multi drug resistant isolates are increasing day by day, due to indiscriminate use of these antibiotics in healthcare 
settings. Reducing and restricting the use of antimicrobials to only those situations where they are warranted, at 
proper dose and for the proper duration is the most appropriate solution.  This hospital-based epidemiological data 
will help to implement better infection control strategies and improve the knowledge of resistance pattern in our 
region. 
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Introduction  
 
Acinetobacter species account for 1to3% of hospital – 
acquired infections and primarily affect immuno-
compromised hosts and patients with comorbid 
diseases.[1]  
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Acinetobacter species are the second most common 
non-fermenting bacteria after Pseudomonas species 
that are isolated from human specimens, especially 
among nosocomial infections[2]. The genus 
Acinetobacter is classified in the family 
Moraxellaceae. Based on DNA hybridization and 
studies on homology groups, there are currently 41 
genome species within the genus Acinetobacter. A. 
baumanii is responsible for the majority of 
Acinetobacter infections; a minority are due to 
A.calcoaceticus, A.lwoffi, A.hemolyticus, A.johnsonni, 
A.junni, A.radioresistens and other genospecies.[3] 
Acinetobacter species are opportunistic pathogens and 
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cause wide-spread hospital infections such as- 
ventilator associated pneumonia, central line associated 
bloodstream infections, post-neurosurgical meningitis, 
catheter associated urinary tract infections, wound and 
soft tissue infections and infections in burn patients. 
Predisposing factors include the presence of a 
prosthesis, endotracheal intubation, intravenous 
catheter, peritoneal dialysis, underlying severe illness, 
long term hospitalization, stays in intensive care units 
(ICUs) and selective antimicrobial pressure.[4] The 
potential source of contamination with Acinetobacter 
in hospital environment is the medical equipments used 
for therapy or from contamination in the environment 
by airborne route or by contact with the patients. Its 
great capacity to survive in low- moist environment 
coupled with its ability to develop resistance to 
antimicrobial agents can also increase the spreading in 
hospitals.[5]The spread of multidrug resistant 
Acinetobacter strains among hospitalized patients has 
become an increasing cause of concern.[6] Therefore, 
treatment of infections caused by these organism 
should be based on antimicrobial susceptibility testing. 
Efficient infection control strategies and strict isolation 
procedure of colonized or infected patients prevent the 
dissemination of these strains to the environment.The 
present study was carried out to know the frequency of 
Acinetobacter spp. in our hospital setting isolated from 
various clinical specimens and to determine their 
antimicrobial susceptibility.  
 
Material and Methods  
 
This retrospective study was conducted in the 
Microbiology department of tertiary care hospital from 
July 2015 to Dec 2016. A total of 261 Acinetobacter   
isolates were recovered from various clinical samples 
like pus/swab, urine, sputum, blood, body fluids, 
tracheal aspirates. The samples received in the 
laboratory were processed according to standard 
procedures and the isolates were identified on the basis 
of colony characteristics, Gram' staining, motility test, 
oxidase test and Triple Sugar Iron agar.[7]  
Acinetobacter spp. were identified by characteristics 
colony appearance, non lactose-fermenting,  gram 
negative coccobacilli, non-motile, oxidase negative, 
catalase positive and alkaline reaction on Triple Sugar 
Iron Agar Test. Further species differentiation was 
done on the basis of Glucose oxidation, citrate test, 
growth at 42℃, fermentation of 10% lactose.(Table1)   
 
Table 1: Identification of isolates 
 
 Glucose oxidation Citrate Test Growth at 42℃ Fermentation of 10% Lactose 
A.baumanni ₊  ₊  ₊  ₊  
A.lwoffi ₋  ₋  ₋  ₋  
 
After identification by phenotypic methods 
antimicrobial susceptibility testing was performed for 
each isolate by Kirby- Bauer disc diffusion method as 
recommended by CLSI guidelines.[8]Multidrug-
resistant (MDR) Acinetobacter spp.are defined as those 
isolates resistant to more than three classes of 
antibiotics, An isolate was classified as pan resistant 
when it was resistant to all of the commonly used 
antibiotics. [9]          
Results 
 
 From 261 Acinetobacter isolates recovered from very 
various clinical specimens, majority (78%) were 
detected from patients admitted in various wards of 
hospital and the rest (22%) were isolated from the OPD 
cases. Majority of the Acinetobacter species were 
isolated from pus/swabs, followed by blood , urine and  
body fluids (4.6%). (Table2). 
 
Table 2: Distribution of Acinetobacter isolates in various clinical specimens 
 
Specimen Percentage of isolates 
Pus/Swab 39.5% 
Blood 31% 
Urine 19.9% 
Body fluids 4.6% 
Tracheal aspirate 2.6% 
Sputum 2.4% 
A.baumanii was the main species responsible for (94%) of the infection, followed by A.lwoffi (6%). (Figure1) 
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Fig 1: Pie diagram showing percentage of  Acinetobacter species isolated in various clinical specimens 
                               
In the present study, most of the  Acinetobacter species 
were  resistant to ciprofloxacin (73.4%), amikacin 
(57.9%),gentamicin (70.4%), ceftazidime (82.9%), 
cefoperazone (82.4%), ampicillin/sulbactum (58%). 
The low resistant pattern of imipenem (23.6%), 
sulbactam-ceftazidime (18.4%) piperacillin/ tazo- 
bactam(15.1%)  indicate that they are effective drugs. 
All the isolates were found to be sensitive to 
colistin.(Table3). 
 
Table 3: Frequency of Antimicrobial resistance in Acinetobacter spp. in various clinical samples 
 
Antimicrobial  Resistant (%) Sensitive (%) 
Ciprofloxacin (5mcg) 73.4 26.6 
Amikacin (30mcg) 57.9 42.1 
Gentamicin (10mcg)  70.4 29.6 
Ceftazidime (30mcg) 82.9 17.1 
Cefoperazone (75mcg) 82.4 17.6 
Ampicillin/Sulbactum (10/10mcg) 58 42 
Sulbactum/ceftazidime (30/10mcg) 18.4 81.6 
Piperacillin/tazobactum (100/10mcg) 15.1 84.9 
Imipenem(10mcg) 23.6 76.4 
Colistin(300units) 0 100 
 
Out of 261 isolates, 57.9% were multidrug-resistant (MDR) and 15.1%were pan-drug resistant (PDR). 
 
Discussion 
 
In this current study the frequency and antibiogram of 
Acinetobacter species isolated from various clinical 
samples in our hospital was studied. Acinetobacter spp 
has emerged as the causative agent of nosocomial 
infection due to increased use of invasive procedures, 
overuse of broad spectrum antimicrobials and 
prolonged duration of stay in the hospital. 
Development of resistance against antimicrobials is a 
major problem in the treatment of Acinetobacter 
infections. Although they are considered as pathogen  
 
 
of mild virulence, they can rapidly acquire 
resistance.[10] 
Acinetobacter normally inhabits soil and water and has 
also been isolated from foods and animals. In humans, 
Acinetobacter can colonize skin, wounds, respiratory 
and gastrointestinal tracts.[11] It is a pathogen of 
tropical and humid environment, but some species can 
survive environmental dessication for weeks, a 
characteristic that promotes transmission through 
fomite contamination in hospitals.[12] Hospital 
environment is heavily contaminated with these 
A.baumanii 
94% 
A.lwoffi 
6% 
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organisms. The carriage rate is much higher among 
hospital staff than community. Unhygienic practices in 
hospital (contaminated hands of staff) and warm 
hospital environment (summers) promote colonization. 
Acinetobacter  persist on inanimate surfaces for 
prolonged periods of time ranging from 3 days to 5 
months and can be detected on various equipment 
including bedrails, curtains, ventilation equipments(e.g. 
AMBU bags, ventilator filter).[13]  Patients with 
underlying diseases or immunosuppression are 
predisposed to invasion and pathogenesis. Virulence 
factors attributed to pathogenesis are Outer membrane 
protein (OmpA), lipopolysaccharide, lipases ability to 
form biofilm and siderophores. [14]Out of 261 isolates 
of Acinetobacter species,78% of Acinetobacter isolates 
were obtained from patients admitted to various wards, 
whereas only 22% were obtained from OPD cases. We 
isolated majority of the Acinetobacter species from 
pus/swabs (39.5%), followed by blood (31%), urine 
(19.9%), body fluids (4.6%) tracheal aspirates (2.6%) 
and sputum (2.4%). Similar findings of majority of 
Acinetobacter spp isolation from pus/swab were also 
obtained by Chakraborty et al. in West Bengal.[15] 
Lone et al. in Srinagar, India reported that majority 
(39.6%) of the Acinetobacter isolates were obtained 
from urine, followed by pus and wound exudates 
(29.5%).[16]In the present study A.baumannii was 
found to be the frequent cause of infections. Like our 
study, W. Nageeb et al., also proved that  A.baumannii 
was the only Acinetobacter spp.encountered in clinical 
specimens and this supported the finding that infections 
by other Acinetobacter spp. are infrequent.[17]  There 
are some other studies which also found that among 
different Acinetobacter spp, A.baumannii was the most 
prevalent in clinical specimens and the most often 
responsible for nosocomial infections.[16,18,19]   
Hospital outbreaks caused by problematic 
microorganisms, like multidrug-resistant Acinetobacter 
baumannii, resulting in increased morbidity and 
mortality, especially in intensive care units, surgical 
wards in a big hospital complexes, have been reported 
worldwide.[20] Also there are many reports, showing 
that persistent hospital environmental contamination 
with A. baumannii strains may play an important role 
in nosocomial dissemination of these 
organisms.[21,22]  Management of Acinetobacter 
infections is huge challenge because of the broad array 
of antimicrobial resistance. The resistance patterns of 
Acinetobacter isolates towards various antimicrobial 
agents were determined by disc diffusion method as 
recommended by CLSI guidelines. In the present study, 
Acinetobacter isolates exhibited the highest resistance 
(82.9%) against ceftazidime followed by cefoperazone 
(82.4%), ciprofloxacin (73.4%), gentamicin (70.4%), 
ampicillin/sulbactum (58%), amikacin (57.9%). The 
low resistant pattern of imipenem (23.6%), sulbactam-
ceftazidime (18.4%) piperacillin/tazobactam (15.1%)  
indicate that they are effective drugs. All the isolates 
were found to be sensitive to colistin. Antimicrobial 
treatment of the clinical infections caused by 
A.baumannii strains, may be compromised by the 
multiple-drug resistance of many isolates to beta-
lactams, aminoglycosides, and fluoroquinolones.[23] In 
a study conducted by Bhattacharya et al in West 
Bengal rates of non- susceptibility are about 80% for 
ceftazidime, 55.5% for amikacin , 52.17% for 
ciprofloxacin,18.2% for piperacillin/tazobactum and 
15% for imipenem respectively.[24] We found the 
corresponding figures for these group of antimicrobials  
to be 82.9%, 57.9% and 73.4%,15.1% and 23.6% 
respectively. Thus in our study higher values were 
recorded for ceftazidime, amikacin , ciprofloxacin and 
imipenem respectively. In our study 57.9% of the 
isolates were Multidrug-resistant (MDR). The other 
studies conducted by Dash et al in Odisha and Mostofi 
et al in Tehran reported MDR isolates to be 54.7% and 
54% respectively.[4] In a review comparing hospitals 
of 10 Asian countries, 1.2-87% of all Acinetobacter 
isolates from patients with Hospital Acquired 
Pneumonia (HAP) were MDR, with MDR strains most 
prevalent in India and Thailand.[25] In a study from 
Pune, about 48% to 68.6% A.baumanni isolates were 
MDR.[26]One report from U.S.A has quoted imipenem 
resistance in Acinetobacter baumanni in the order of 
23.1%.[27] 
Taneja et al. in Chandigarh, India studied 224 
A.baumanii isolates , out of which  22.3% isolates were 
resistant to carbapenems.[4] Our results show that 
about 23.6% were resistant to imipenem which is 
similar to reports from U.S.A and India..We found that 
imipenem and piperacillin/tazobactum were most 
potent antibiotics against this pathogen. Differences 
observed between the studies could be due to the 
methods and the resistance patterns that are influenced 
by the environmental factors and the antimicrobial 
patterns used.Colistin retains activity against 
Acinetobacter spp. in the face of broad-spectrum 
antimicrobial resistance and have become the last 
resort of treatment. A delay in the administration of 
colistin, has the potential to increase the risk of 
mortality. However, A.baumannii can develop 
resistance to colistin, and thus extreme vigilance is 
required to diagnose the development of resistance 
during treatment. Unfortunately, resistance to colistin 
has emerged with its increasing use, and the recent 
observation of heteroresistance to colistin among 
clinical strains of MDR A.baumannii is also a 
significant cause of concern. Pan drug resistance 
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typically is the result of the convergence of multiple 
resistance mechanisms.[28]  Pan drug resistant  
A.baumannii isolates, i.e  isolates resistant to all 
antimicrobial agents in-vitro, have been reported from 
Asia and the Middle-East. In our study 15.1% isolates 
were pan drug resistant. Colistin retains activity against 
PDR Acinetobacter spp. but side effects like 
nephrotoxicity and ototoxicity limits its use.[13] Our 
study did not find  any Acinetobacter isolate resistant 
to colistin, which may be due to its selective use only 
in case of carbapenem- resistant gram-negative 
bacteria. Colistin activity can be enhanced when 
combined with some other modes of action such as 
carbapenems, rifampicin and ceftazidme. Combination 
therapy of colistin and meropenem has synergistic 
effect/additive effect. Colistin acts on outer membrane 
of cell wall and creates pores allowing the other drugs 
to enter into the bacterial cell. Meropenem has 
bactericidal activity and binds to PBP of cell wall and 
inhibits cell wall synthesis.[28]Although antibiotic 
resistance is a worldwide concern, it is first and 
foremost a local problem- selection for and 
amplification of resistant members of a species that are 
occurring in individual hospitals and communities, 
which can then spread worldwide.[4]The primary goals 
for the control of multidrug resistant Acinetobacter 
infection are recognizing its presence in a hospital  at 
an early stage and controlling its spread. Hospital-
acquired infections are best controlled by following 
appropriate sterile techniques and infection control 
guidelines and by implementing effective protocols for 
the sterilization and decontamination of medical 
supplies. Infection control measures such as improved 
hand hygiene are essential to prevent nosocomial 
infections due to Acinetobacter.      
Conclusion 
A.baumannii is an important nosocomial pathogen 
causing significant morbidity and mortality. MDR 
isolates are increasing day by day, probably due to 
indiscriminate use of these antibiotics in healthcare 
settings. Reducing and restricting the use of 
antimicrobials to only those situations where they are 
warranted, at proper dose and for the proper duration is 
the most appropriate solution. Susceptibility testing 
should be done to help select the best antimicrobial 
drugs for therapy. A combination of a review of hand-
washing practice, education about spread of bacteria 
via hands and contaminated environment, and the 
revision of infection control procedures would help in 
the control of this organism in hospitals. 
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